Valeda -
Dry Macula Degeneration Treatment
Age-related macula degeneration (AMD) is the leading cause of blindness in adults over 65. There are two forms of AMD: dry and wet. Approximately 90% of patients with AMD have the dry form and 10% have the wet form. Orriss & Low Optometrists are proud to introduce the 1st approved European treatment for dry age related macular degeneration (AMD).
Normal vision
Mild Macula degeneration
Progressive Macula degeneration
Dry Age related Macula Degeneration can result in irreversible, severe sight loss affecting ones quality of life. In the last few years a proven treatment for dry AMD has been developed.
Previously patients were expected to stabilise the condition by lifestyle changes, sunlight protection, supplements and the cessation of smoking. Now LumiThera have developed the Valeda device which harnesses photobiomodulation for safe and effective treatment of dry AMD.
Valeda uses low-level wavelengths of light therapy to energise and provide oxygen to the retinal cells.
The lightsite 1 study showed an improvement in vision, increased contrast sensitivity and a reduction in retinal metabolic waste (drusens).
The other benefit of Valeda is a reduction in inflammation and general slowing of the progression of AMD. LumiThera are currently trialling other uses of photobiomodulation suchas for the treatment of diabetic maculopathy.
At Orriss and Low Optometrists we have the sophisticated equipment to firstly diagnose AMD with the use of Optomap retinal imaging and OCT scanners.
The Valeda treatment involves 9 sessions over a 3-week period (1 block). The treatment is repeated every 6 months with our optometrists reviewing and analysing your eye health in between the treatment blocks. The ongoing Valeda treatment is comparable to physiotherapy of the eye.
Book Now
Book now to see one of our wonderful clinical Optometrists!